Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Xilio Therapeutics Inc.

    NASDAQ: XLO · Real-Time Price · USD
    0.69
    0.01 (1.55%)
    At close: Jun 27, 2025, 3:59 PM
    0.69
    -0.28%
    After-hours: Jun 27, 2025, 05:33 PM EDT

    Xilio Therapeutics Statistics

    Share Statistics

    Xilio Therapeutics has 51.78M shares outstanding. The number of shares has increased by 40.26% in one year.

    Shares Outstanding

    n/a
    		 51.78M

    Shares Change (YoY)

    n/a
    		 40.26%

    Shares Change (QoQ)

    n/a
    		 17.78%

    Owned by Institutions (%)

    n/a
    		 40.74%

    Shares Floating

    n/a
    		 16.42M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,970

    FTD / Avg. Volume

    n/a
    		 0.15%

    Short Selling Information

    The latest short interest is 791.48K, so 1.53% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 791.48K

    Short % of Shares Out

    n/a
    		 1.53%

    Short % of Float

    n/a
    		 2.24%

    Short Ratio (days to cover)

    n/a
    		 1.3

    Valuation Ratios

    The PE ratio is -0.88 and the forward PE ratio is -0.85. Xilio Therapeutics's PEG ratio is 0.01.

    PE Ratio

    n/a
    		 -0.88

    Forward PE

    n/a
    		 -0.85

    PS Ratio

    n/a
    		 8.06

    Forward PS

    n/a
    		 3.5

    PB Ratio

    n/a
    		 2.9

    P/FCF Ratio

    n/a
    		 -2.78

    PEG Ratio

    n/a
    		 0.01
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Xilio Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 2.21, with a Debt / Equity ratio of 0.46.

    Current Ratio

    n/a
    		 2.21

    Quick Ratio

    n/a
    		 2.21

    Debt / Equity

    n/a
    		 0.46

    Debt / EBITDA

    n/a
    		 -0.14

    Debt / FCF

    n/a
    		 -0.44

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $99,125

    Profits Per Employee

    n/a
    		 $-910,015.62

    Employee Count

    n/a
    		 64

    Asset Turnover

    n/a
    		 0.09

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 n/a

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by -27.66% in the last 52 weeks. The beta is 0.02, so Xilio Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.02

    52-Week Price Change

    n/a
    		 -27.66%

    50-Day Moving Average

    n/a
    		 0.77

    200-Day Moving Average

    n/a
    		 0.87

    Relative Strength Index (RSI)

    n/a
    		 44.61

    Average Volume (20 Days)

    n/a
    		 1,282,061

    Income Statement

    In the last 12 months, Xilio Therapeutics had revenue of 6.34M and earned -58.24M in profits. Earnings per share was -1.09.

    Revenue

    n/a
    		 6.34M

    Gross Profit

    n/a
    		 6.34M

    Operating Income

    n/a
    		 -60.58M

    Net Income

    n/a
    		 -58.24M

    EBITDA

    n/a
    		 -58M

    EBIT

    n/a
    		 -59.65M

    Earnings Per Share (EPS)

    n/a
    		 -1.09
    Full Income Statement

    Balance Sheet

    The company has 55.29M in cash and 8.14M in debt, giving a net cash position of 47.15M.

    Cash & Cash Equivalents

    n/a
    		 55.29M

    Total Debt

    n/a
    		 8.14M

    Net Cash

    n/a
    		 47.15M

    Retained Earnings

    n/a
    		 -383.75M

    Total Assets

    n/a
    		 103.72M

    Working Capital

    n/a
    		 45.56M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -18.38M and capital expenditures -36K, giving a free cash flow of -18.41M.

    Operating Cash Flow

    n/a
    		 -18.38M

    Capital Expenditures

    n/a
    		 -36K

    Free Cash Flow

    n/a
    		 -18.41M

    FCF Per Share

    n/a
    		 -0.34
    Full Cash Flow Statement

    Margins

    Gross margin is 74.09%, with operating and profit margins of -954.95% and -918.05%.

    Gross Margin

    n/a
    		 74.09%

    Operating Margin

    n/a
    		 -954.95%

    Pretax Margin

    n/a
    		 -918.05%

    Profit Margin

    n/a
    		 -918.05%

    EBITDA Margin

    n/a
    		 -890.56%

    EBIT Margin

    n/a
    		 -954.95%

    FCF Margin

    n/a
    		 -290.26%

    Dividends & Yields

    XLO does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for XLO is $4, which is 488.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $4

    Price Target Difference

    n/a
    		 488.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 1
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -6.23

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist